Protein Expression Market Overview
The global protein expression market size was $ 1.4 billion in 2016, which is expected to reach $ 3.0 billion by 2023, growing at a CAGR of 11.7% during the forecast period (2017-2023). Protein expression refers to a process by which proteins are synthesized, altered and regulated in living organisms. In protein research, the term (protein expression) can apply to either the object under study or the laboratory techniques that are required to manufacture proteins. Protein expression is an important part of proteomics study that allows the expression of recombinant proteins in various host systems.
GLOBAL PROTEIN EXPRESSION MARKET, BY PRODUCT AND SERVICES, $M (2013 – 2023)
On the basis of system, the protein expression market is segmented into prokaryotic expression systems, mammalian cell expression systems, insect cell expression systems, yeast expression systems, cell-free expression systems and algal-based expression systems. Prokaryotic expression systems registered the largest share in 2016, since they are cheaper as compared to the other expression systems such as mammalian cell expression systems, and insect cell expression systems.
Based on product and services, the market is bifurcated into reagents, expression vectors, competent cells, instruments and services. The report indicates that reagents are expected to hold the largest share of the protein expression market during the forecast period, owing to increasing protein expression research activities and the large-scale production of antibodies and vaccines.
Protein expression finds application in therapeutic, industrial and research areas. Therapeutic is expected to witness the largest share of the market during the forecast period, due to increasing prevalence of chronic diseases such as cancer and diabetes around the world, and high efficacy of protein therapeutics.
The end users of protein expression market include pharmaceutical and biotechnology companies, academic research institutes, contract research organizations and other users. The biotechnology and pharmaceutical companies are expected to occupy the largest share during the forecast period, mainly due to the technological advancement in protein expression research and rising production of recombinant therapeutic proteins for disease treatment.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. North America dominated the global market in 2016 followed by Europe. Asia-Pacific is expected to register the fastest growth during the forecast period, owing to rising prevalence of diseases such as cardiovascular disease and diabetes, growing aging population, increasing R&D spending and rising per capita income.
Protein Expression Market Dynamics
Key factors driving the growth of the global protein expression market include increasing prevalence of chronic diseases, rise in the availability of funding for protein-based research, technological advancements, growing aging population and increasing growth in the life science sector. The factors that impede the growth of the market include, increasing market consolidation and high cost of protein expression reagents and instruments.
Healthcare industry has been undergoing rapid changes in the emerging economies due to rising government expenditure, increasing number of hospitals, increase in the number of surgeries, and rising healthcare awareness. In emerging economies such as India, China, Brazil, and Mexico, the share of government spending on healthcare has increased significantly over the past. According to World Bank, Brazil spent 8.3% of its $2.5 trillion GDP on healthcare in 2014. Similarly, China spent 5.5% of its total GDP on healthcare, and Mexico spent 6.3% of its total GDP on healthcare in the same year. The exploration of these emerging economies would provide plenty of opportunities to the key players in the protein expression market.
The increase in prevalence of chronic diseases requires clinical intervention to ameliorate the diseases, which is attained by increasing research and development in the protein expression field. Chronic diseases include cancer, hepatitis, chronic obstructive pulmonary disease (COPD), cardiovascular diseases and viral diseases such as HIV. According to the WHO, chronic diseases are a leading cause of mortality globally, comprising 60% of all deaths. Among all the chronic diseases, cardiovascular diseases are the leading cause of deaths, globally. Also, approximately 17.7 million people died from cardiovascular disease in 2015, representing 31% of the global deaths. Of these deaths, approximately 7.4 million deaths were due to coronary heart disease and 6.7 million were due to stroke.
To understand the normal functionality of cell and to identify the changes that lead to protein dysfunction during diseases, has fuelled protein-based research industry. These researches are funded by public and private organizations to deduce therapeutic approaches. The National Institute of Health (NIH), one of the world’s foremost medical research center, invests nearly $32.3 billion annually in medical research and supports by offering grants to projects and programs in life sciences and the medical field. Some of NIH funded programs include Protein Structure Initiative (PSI), Protein capture reagents program.
The Novo Nordisk Foundation Center for protein research, established in collaboration with University of Copenhagen in 2007, granted a total of €104,8 million till 2014 to establish and further develop the centers in protein research. Major key players in the biotechnology and pharmaceutical industry such as ThermoFisher Scientific, Merck KGaA also invest in R&D to expand in the field of protein research. ThermoFisher Scientific R&D spend $750 million in 2016 in comparison to $240 million in 2015.
Protein Expression Market Competitive Landscape
Due to extensive development and high competition in the protein expression market, the companies are focusing on acquiring other players to increase their product portfolio.
In January 2017, Takara Bio USA Holdings, Inc. (“TBUSH”), a wholly owned subsidiary of Takara Bio Inc, completed the acquisition of Rubicon Genomics, Inc, that develops nucleic acid library preparation and companion products that enable highly sensitive analysis of clinical research samples around the world. Under the merger agreement executed with Rubicon, TBUSH paid $75 million to acquire 100% of the equity in Rubicon.
Some of the other key players operating in this industry include Thermo Fisher Scientific Inc., Merck KGaA, Genscript Biotech Corporation, Agilent Technologies, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., New England Biolabs Inc., and Lonza Group Ltd.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Period of Analysis – Increase in the study period, including historic and forecast years
Geographical Analysis – Increase in country coverage
Segment Analysis – More granular coverage related to:
Further analysis of end user under protein expression by region
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles
New custom report – A completely customized report can be provided on the market, specific to a region/ country/ segment